Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51

Benzinga · 2d ago
Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $50 to $51.